Fresenius Kabi specializes in lifesaving medicines and technologies for critically and chronically ill patients and focuses on improving healthcare results. The company is involved in the fields of Pharma, Nutrition, MedTech, and Biopharma.

Fresenius Kabi

Activ Surgical is involved in the development of surgical technologies and tools. Self-described as innovative, it focuses on enhancing surgical procedures through its technological offerings.

Activ Surgical

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Formycon AG

Grünenthal is a science-based, privately-owned pharmaceutical company focused on pain management and related diseases.

Metric
Company Name	Fresenius Kabi	Activ Surgical	Formycon AG	Grünenthal
Symbol			FYB
MSH ID	COM:FRESENIUS-KABI	COM:ACTIVSURGICAL	COM:FORMYCON	COM:GRUNENTHAL
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Medical Devices	Biotechnology	Pharmaceuticals
Country	DE	US	DE	DE
Stage
Employee Count	10.00K		238
Website	fresenius-kabi.com	activsurgical.com	formycon.com	grunenthal.com
LinkedIn
Founders

Metric
Market Cap			1.02B
Enterprise Value
Monthly Web Traffic			6.53K
Web Traffic Growth			0.44
Valuation
Raised Capital

Metric
Revenue			82.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit			24.62M
EBITDA			1.54M
Operating Income			-452.07K
Net Income			80.06M
EPS			5.03
Diluted EPS			4.99
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.36
Operating Profit Margin			-0.01
EBITDA Margin			0.02
Net Profit Margin			1.05
Return on Equity			0.16
Return on Assets			0.09
Return on Capital Employed			-0.00

COM:FRESENIUS-KABI

Fresenius Kabi

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			17.76
P/B Ratio			1.39
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			15.54
EV Multiple			689.86

Metric
Days Sales Outstanding			95.46
Days Payables Outstanding			2.81K
Days Inventory Outstanding			14.57
Operating Cycle			251.88
Cash Conversion Cycle			135.65
Asset Turnover			0.09

Metric
Operating Cash Flow			-9.93M
Free Cash Flow			-32.32M
Cash Flow to Debt			-0.32
Operating Cash Flow/Sales			-0.12
Free Cash Flow Yield			-0.06

Metric
Cash & Equivalents			28.56M
Accounts Receivable			-13.42M
Inventory			493.26K
Goodwill			47.04M
Debt to Capitalization			0.06
Debt to Assets
Current Ratio			0.46
Quick Ratio			2.06

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.01
R&D to Revenue			0.40
SG&A to Revenue			0.27